

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.

百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

DATE OF AUDIT COMMITTEE MEETING

BeiGene, Ltd. (the “**Company**”) hereby announces that a meeting of the audit committee of the board of directors (the “**Board**”) will be held on August 25, 2023 (Hong Kong Time) for the purposes of, inter alia, considering and approving the interim results of the Company and its subsidiaries for six months ended June 30, 2023 and its publication in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”). The Company previously announced its interim results for the three and six months ended June 30, 2023 and filed its Quarterly Report on Form 10-Q with the United States Securities and Exchange Commission (the “**SEC**”) on August 2, 2023. **The interim results being published by the Company in accordance with the Hong Kong Listing Rules are the same as previously announced by the Company and filed with the SEC, except for specific additional information required by the Hong Kong Listing Rules, together with a reconciliation of the Company’s interim results from U.S. Generally Accepted Accounting Principles to International Financial Reporting Standards.**

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, August 14, 2023

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi as Independent Non-executive Directors.